Literature DB >> 24533959

Acquired haemophilia A after stem cell transplant for sickle cell disease: treatment with recombinant porcine factor VIII (OBI-1) and tolerance induction with rituximab/prednisone.

J N Lozier1, K Nghiem, M Lee, B Hodsdon, G Joe, R P Weitzel, J F Tisdale, M Hsieh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24533959      PMCID： PMC5536239          DOI： 10.1111/hae.12372

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  8 in total

1.  Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.

Authors:  M Algiman; G Dietrich; U E Nydegger; D Boieldieu; Y Sultan; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.

Authors:  C M Kessler; C A Ludlam
Journal:  Semin Hematol       Date:  1993-04       Impact factor: 3.851

3.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Authors:  Matthew M Hsieh; Elizabeth M Kang; Courtney D Fitzhugh; M Beth Link; Charles D Bolan; Roger Kurlander; Richard W Childs; Griffin P Rodgers; Jonathan D Powell; John F Tisdale
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

4.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

5.  Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

Authors:  Shawn F J Whelan; Christoph J Hofbauer; Frank M Horling; Peter Allacher; Martin J Wolfsegger; Johannes Oldenburg; Christoph Male; Jerzy Windyga; Andreas Tiede; Hans Peter Schwarz; Friedrich Scheiflinger; Birgit M Reipert
Journal:  Blood       Date:  2012-12-12       Impact factor: 22.113

6.  Acquired haemophilia caused by non-haemophilic factor VIII gene variants.

Authors:  Andreas Tiede; Roswith Eisert; Andreas Czwalinna; Wolfgang Miesbach; Inge Scharrer; Arnold Ganser
Journal:  Ann Hematol       Date:  2010-01-07       Impact factor: 3.673

7.  Use of porcine factor VIII in the treatment of patients with acquired hemophilia.

Authors:  A E Morrison; C A Ludlam; C Kessler
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

8.  Inhibitors of factor VIII in black patients with hemophilia.

Authors:  Kevin R Viel; Afshin Ameri; Thomas C Abshire; Rathi V Iyer; Raymond G Watts; Charles Lutcher; Cynthia Channell; Shelley A Cole; Karl M Fernstrom; Shelley Nakaya; Carol K Kasper; Arthur R Thompson; Laura Almasy; Tom E Howard
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245
  8 in total
  4 in total

Review 1.  Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

Review 2.  Rituximab for eradicating inhibitors in people with acquired haemophilia A.

Authors:  Tracey Remmington; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23

3.  Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.

Authors:  Kelsey Uminski; Roy Khalife; Natasha Kekre; Alan Tinmouth
Journal:  Ann Hematol       Date:  2022-03-21       Impact factor: 4.030

Review 4.  [Post-transplantation lymphoproliferative disorder accompanies acquired hemophilia after haploid hematopoietic stem cell transplantation in a pediatric AML patient: a case report and literature review].

Authors:  X L Jiao; Y Q Wang; H Ai; Q Wang; H Zhou; Y W Fu; X D Wei; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.